As part of the agreement, Gene by Gene, parent company of FamilyTreeDNA, will support DNA uploads generated from the Verogen ForenSeq Kintelligence kit, the only ANAB accredited technology approved for forensic investigative genetic genealogy.
This partnership effectively doubles the number of profiles available for FIGG matching.
Leveraging database knowledge, scientists from both organizations will also create superior algorithms and software that increase the probability of generating uploadable single nucleotide polymorphism profiles and lower bioinformatic costs enabling standardization of the FIGG workflow.
FIGG is a DNA-based investigative lead-generation technique that leverages genotyping and next-generation sequencing technologies to identify perpetrators of violent crime, exonerate the innocent, and identify missing persons.
Verogen's GEDmatch database and Gene by Gene's genealogical database are the only databases that enable FIGG and have cumulatively helped resolve over 500 cold cases that were previously considered unsolvable.
This long-term partnership aims to ensure that all uploads adhere to the terms set forth by Verogen and Gene by Gene, including existing requirements to opt-in to the genetic witness program to show up as a familial connection, and standardize analysis options and bioinformatic methods.
Verogen is a dedicated developer of DNA-based biometric human identification products for analysis of forensic genomic samples.
Founded in 2000, Gene by Gene provides genetic testing services to a range of consumers and institutional customers through its four divisions focusing on ancestry, health, research, and paternity.
Gene by Gene is a CAP/CLIA/NYSDOH accredited laboratory and, through its clinical health division, offers health, wellness, and regulated diagnostic testing services.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients